by Greg Kuehn | Sep 5, 2019 | Press Releases
CARLSBAD, Calif., Sept. 4, 2019 /PRNewswire/ — Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company’s submission...
by Greg Kuehn | Mar 17, 2014 | Research News
Chevy Chase, MD, March 17, 2014 Metabiomics is pleased to announce the launch of a new IRB approved microbiome clinical research study titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01. The ~200 patient study will be conducted in...
